The use of PET/ CT with a hypoxia marker (18F-MISO) in radiotherapy treatment planning

Czech version

Authors: Tomáš Novotný ¹; Zdeněk Řehák ²; Michal Budinský ³; Petr Dvořáček ⁴; Jiří Vašina ²; Pavel Šlampa ¹; Marek Slávik ¹
Authors‘ workplace: Klinika radiační onkologie LF MU a MOÚ, Brno ¹; Oddělení nukleární medicíny, MOU Brno ²; Ústavní lékárna, MOÚ Brno ³; Oddělení radiologické fyziky, MOÚ Brno ⁴
Published in: Klin Onkol 2021; 34(3): 241-243
Category: Oncology in Images
doi: https://doi.org/10.48095/ccko2021241

Sources

Hodolič M, Fettich J, Kairemo K. Hypoxia PET tracers in EBRT dose planning in head and neck cancer. Curr Radiopharm 2015; 8(1): 32–37. doi: 10.2174/ 1874471008666150316222400.
Watanabe S, Inoue T, Okamoto S et al. Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy. [online]. Available from: https:/ / ejnmmires.springeropen.com/ articles/ 10.1186/ s13550-019-0578-6.
Specifické léčebné programy. [online]. Dostupné z: https:/ / www.radiomedic.cz/ produkty/ specificke-lecebne-programy/
Pigorsch SU, Wilkens JJ, Kampfer S et al. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. Radiat Oncol 2017; 12(1): 45. doi: 10.1186/ s13014-017-0776-1.